



Defense Health Agency SBIR/STTR Program: Enabling Biomedical and Healthcare Solutions

CDR Tatana Olson, Program Director

June 13, 2022

UNCLASSIFIED



Agency Introduction

- DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force
- Supports the delivery of integrated, affordable, and high quality health services to more than 10 million Military Health System (MHS) beneficiaries
- Supports the Assistant Secretary of Defense for Health Affairs in management and oversight of Defense Health Program (DHP) RDT&E appropriation (does not execute research efforts)
- Manages and execute S&T funds, ensuring they align to requirements and are positioned to transition into formal product development efforts



UNCLASSIFIED







DHA SBIR/STTR Programs

- DHA SBIR/STTR Annual budget:
 - FY22 SBIR \$66.7 Million, FY22 STTR \$9.4 Million
- Provide Phase I and Phase II funding opportunities
- Direct to Phase II, Phase II Enhancement, and Sequential Phase II mechanisms are also utilized on a limited basis
- In-house transition assistance through a Technical Assistance Advocate begins at the awarding of a Phase I contract
- Topics align to broader research program areas, which is important to supporting transition into product development
- Topics typically appear on the DoD SBIR/STTR main BAA cycles, but special cycles may be issued; be certain to join the DoD SBIR/STTR mailing list on DSIP



UNCLASSIFIED



Biomedical R&D Investment Approach

Primarily targeted in areas, or environments, that are militarily unique for which there are limited or no commercial partners or interests

- The DoD leads in key biomedical research areas: e.g. prolonged field care, en route care, forward surgical/intensive critical care, hemorrhage control and blood products
- The DoD leverages in areas where commercial technologies exist and can be tailored for military use: e.g. medical simulation and training, diagnostic systems, pain management, infectious diseases
- The DoD watches areas of emerging interest: e.g. Medical Radiological Defense and other tech areas like Artificial Intelligence

How can we apply this approach?



UNCLASSIFIED



UNCLASSIFIED

RDT&E Major Investment Areas



Military Operational Medicine

- Musculoskeletal injury prevention and reduction
- Blunt, blast, accelerative, and neurosensory injury prevention and readiness
- Psychological health & resilience
- Performance in extreme environments
- Optimized cognition & fatigue mitigation

Combat Casualty Care

- Neurotrauma
- Hemorrhage control & battlefield resuscitation
- Prolonged Care
- Severe burn
- En Route Care
- Autonomous care & evacuation
- Radiation health countermeasures
- Sustainment of medical expeditionary skills
- Military medical photonics

UNCLASSIFIED

Medically Ready Force... Ready Medical Force

Military Infectious Diseases

- Viral
- Bacterial
- Wound Healing





Recent DHA SBIR/STTR Topic Examples

• Military Infectious Diseases


- Rapid Purification for Therapeutic Use of Bacteriophages That Target Gram-Negative Bacterial Species
- Material Solutions to Bacteriophage Stabilization/Application in Austere Environments
- Military Operational Medicine
 - Remote Frostbite Prevention System
 - Olfactory Neuroepithelium Functional Diagnostic Tool
- Combat Casualty Care
 - Medicated Combat Tourniquet Capable of Wound Infection Treatment Delivery
 - Dissolvable Materials for Photochemical Tissue Bonding



UNCLASSIFIED



DHA SBIR/STTR Process Flow








DoD SBIR/STTR BAAs

- DoD SBIR/STTR Office establishes six DoD SBIR/STTR Broad Agency Announcements (BAA) and respective mandated dates, as well as special cycle opportunities
- BAAs are numbered chronologically. For FY2022, 3 SBIR BAAs published: 21.1, 22.2, and 22.4*







Proposal Tips

- Read the BAA thoroughly
- Take advantage of the pre-release period of the Broad Agency Announcement when you can contact topic authors directly
- Don't miss critical Phase II proposal information on the topic
 - You are never just proposing to the Phase I—the Phase I is intended to prove the feasibility of your approach to Phase II
- Phase III is the author's working concept of the future state of the technology, but it is always a good idea to identify additional commercial potential.
- Submit early!
- Ultimately, successful DHA SBIR and STTR efforts must demonstrate a better/faster/cheaper approach with a meaningful non-DoD market and attention to fielding specifics









DHA SBIR/STTR Team

Mr. JR Myers, Project Manager

Ms. Colleen Gibney, Deputy Project Manager

Ms. Dominique Quesada, Operations Manager

Ms. Amanda Cecil, Program Analyst

Ms. Danielle Wilson, Program Analyst

Ms. Andrea Renner, Technical Assistance Advocate (Transition)

Contact us: DHA_SBIR-STTR@mail.mil

UNCLASSIFIED







Questions?



UNCLASSIFIED



